14 patents
Utility
Genes and gene signatures for diagnosis and treatement of melanoma
5 Dec 23
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 20 May 21
Utility
Genes and Gene Signatures for Diagnosis and Treatment of Melanoma
26 Oct 23
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan WARF, Benjamin ROA, Alexander GUTIN, Darl FLAKE
Filed: 3 Feb 23
Utility
Diagnostic Test for Predicting Metastasis and Recurrence In Cutaneous Melanoma
16 Mar 23
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis COOK, Derek MAETZOLD, Kristen OESCHLAGER
Filed: 8 Aug 22
Utility
Genes and gene signatures for diagnosis and treatment of melanoma
21 Feb 23
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 10 Feb 20
Utility
Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores
8 Sep 22
Example embodiments relate to determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores.
Kyle R. COVINGTON, Bernhard SPIESS, Ann QUICK, Sarah KURLEY
Filed: 7 Mar 22
Utility
Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
6 Sep 22
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis Cook, Derek Maetzold, Kristen Oeschlager
Filed: 17 Jan 20
Utility
Genes and Gene Signature for Diagnosis and Treatment of Melanoma
4 Aug 22
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Darl FLAKE, Alexander GUTIN, Douglas ADAMS
Filed: 26 Nov 21
Utility
Genes and Gene Signatures for Diagnosis and Treatement of Melanoma
31 Mar 22
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 20 May 21
Utility
Methods of Diagnosing and Treating Patients with Pigmented Skin Lesions
3 Feb 22
The present disclosure relates to methods for diagnosing a skin lesion as malignant or benign.
Robert Willis COOK, Derek MAETZOLD, Kyle R. COVINGTON, Olga ZOLOCHEVSKA
Filed: 3 Aug 21
Utility
Methods of Diagnosing and Treating Patients with Cutaneous Squamous Cell Carcinoma
5 Aug 21
The present disclosure relates to methods for predicting the risk of recurrence and/or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).
Robert Willis COOK, Kyle R. COVINGTON, Derek MAETZOLD, Sarah J. KURLEY
Filed: 31 Jan 20
Utility
Methods of Diagnosing and Treating Patients with Cutaneous Squamous Cell Carcinoma
5 Aug 21
The present disclosure relates to methods for predicting the risk of recurrence and/or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).
Robert Willis COOK, Kyle R. COVINGTON, Derek MAETZOLD, Sarah J KURLEY
Filed: 14 Aug 20
Utility
Diagnostic Test for Predicting Metastasis and Recurrence In Cutaneous Melanoma
18 Nov 20
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis COOK, Derek MAETZOLD, Kristen OESCHLAGER
Filed: 16 Jan 20
Utility
Methods for Predicting Risk of Recurrence And/or Metastasis In Soft Tissue Sarcoma
21 Oct 20
The disclosure related to the development of a gene expression profile to predict soft tissue sarcoma (STS) recurrence, distant metastasis, or both.
Robert Willis COOK, Weiwei SHAN, Derek MAETZOLD
Filed: 4 Jun 17
Utility
Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
2 Mar 20
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis Cook, Derek Maetzold, Kristen Oeschlager
Filed: 18 Mar 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first